The international conference New Frontiers in Structure-Based Drug Discovery is jointly established by the European MSC Innovative Training Networks AEGIS and TASPPI at Convitto della Calza in Florence, Italy.
The meeting will run from 12:00 Mon, Sep 23 to 16:00, Wed, Sep 25, 2019
Program
Download program
| Joint International Conference | |
| New Frontiers in Structure-based Drug Discovery | |
| Program | |
| Monday, Sep 23, 2019 | Key note lectures: 35+5 min, Talks: 15+5 min, Flash Talk: 2 min |
| 12:45 | Welcome Michael Sattler, Christian Ottmann |
| SESSION 1 – Structure- and Fragment-based Drug Discovery | |
| Chair: Christian Ottmann | |
| 13:00 | Keynote lecture: Stephen Fesik Cancer Drug Discovery Using Fragment-Based Methods and Structure-Based Design |
| 13:40 | Francesco Bosica Mg2-assisted small-molecule stabilisation of 14-3-3 Protein-Protein Interactions. |
| 14:00 | Barak Akabayov Development of antibacterial agents that target the ribosomal PTC of M. tuberculosis |
| 14:20 | Christian Griesinger Modulation of aggregating proteins studied by NMR and beyond in neuro- and cellular degeneration |
| 14:40 | Madita Wolter Drug Discovery at the Boundary of Cancer and Infection |
| 15:00 | Keynote lecture: Mike Hann ‘PhABits – shining new light on fragment approaches for assessing target tractability' |
| 15:40 | Coffee Break |
| SESSION 1 – cont'd | |
| Chair: Tomáš Obšil | |
| 16:10 | João Neves Nuclear Magnetic Resonance guided screening applied to the discovery of modulators of 14-3-3 Protein-Protein Interactions |
| 16:30 | Stefan Hoerer Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule |
| 16:50 | Keynote lecture: Edward Tate Fragment-guided discovery of an irresistible antiviral protein-protein interaction inhibitor |
| 17:30 | Flash Talks |
18:45 | Poster Session 1 with drinks |
| Tuesday, Sep 24, 2018 | |
| SESSION 2 – Intrinsically Disordered and Amyloidogenic Proteins | |
| Chair: Isabelle Landrieu | |
| 09:00 | Keynote lecture: Birthe Kragelund Disordered Protein Complexes |
| 09:40 | Orgeta Zeijneli A VHH directed against tau as a novel therapeutic approach in tauopathies |
| 10:00 | Carlos Camacho Neuroprotection by small molecule inhibition of disordered peptide and syntaxin interaction |
| 10:20 | Coffee Break |
| SESSION 3 – Chemical biology, targeting & new concepts | |
| Chair: Alex Dömling | |
10:50 | Keynote lecture: Alessio Ciulli Targeted Protein Degradation with Small Molecules: How PROTACs work |
| 11:30 | Felix Hausch Selective FKBP51 inhibitors enabled by transient pocket binding |
| 11:50 | Markella Konstantinidou Discovery of proteolysis targeting chimeras for leucine-rich repeat kinase 2 (LRRK2) |
| 12:10 | Nikolaos Sgourakis New tools for the analysis of polyclonal T cell repertoires using chaperone-mediated peptide exchange |
| 12:30 | Valeria Napolitano Inhibition of glycosomal protein import: the sweet death of Trypanosoma |
| 12:50 | Lunch |
| SESSION 3 – cont'd | |
| Chair: Alex Dömling | |
| 14:20 | Keynote lecture: Michelle Arkin Chemical Biology Approaches to Understanding the VCP/p97 Protein Interaction Network |
| 15:00 | João Encarnação Bioengineering subunit B from Shiga Toxin 1 for intracellular drug delivery |
| SESSION 4 – Peptides, natural products and non-small molecules | |
| Chair: Andrew Wilson | |
| 15:20 | Keynote lecture: Ora Schueler-Furman Peptide as leads for targeted inhibition of interactions – How free, how determined? |
| 16:00 | Helen Boyd Identification of a novel cyclic peptide that disrupts the homodimerization of the E3 ubiquitin ligase IDOL |
| 16:20 | Coffee Break |
| SESSION 4 – cont'd | |
| Chair: Andrew Wilson | |
| 16:50 | Françoise Ochsenbein Rational Design of Peptides and Foldamers inhibiting a New Epigenetic Target in Cancer |
| 17:10 | Grzegorz Dubin Macrocycle mediated inhibition of PD-1/PD-L1 immune checkpoint |
| 17:30 | Katiuscia Pagano Design of antiangiogenic agents targeting Fibroblast Growth Factors-2/Tyrosine-Kinase Receptor |
| 17:50 | Federica De Leo Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment |
| 18:10 | Xiao-Ling Cockcroft New Paradigm for Finding Natural-product-like KRAS Inhibitors |
| 18:30 | Keynote lecture: Patricia Aducci Fusicoccin and 14-3-3 proteins, a long story from plant pathology to drug design. |
| 19:10 - 20:30 | Poster Session 2 |
| 20:30 - 23:00 | Gala Dinner |
| Wednesday, Sep 25, 2018 | |
| SESSION 5 – Computational Drug Discovery | |
| Chair: Helena Danielson | |
| 09:00 | Keynote lecture: Rebecca Wade Computational Approaches to Protein Dynamics and Binding Kinetics for Drug Discovery |
| 09:40 | Marcus Gastreich Debunking a myth - Can σ-Holes Really Drive Affinity? |
| 10:00 | Alessandro Paiardini Identification of small-molecule inhibitors of the Aurora-A/TPX2 complex |
| SESSION 6 – Structural biology, biophysics & methods | |
| Chair: Michael Nilges | |
| 10:20 | Sebastian Guenther Serial Crystallography for Ligand-Binding Studies |
| 10:40 | Charlotte Softley Placing fragments with lanthanide tags using paramagnetic NMR |
| 11:00 | Coffee Break |
| SESSION 6 – cont'd | |
| Chair: Michael Nilges | |
| 11:30 | Claire Munier Small molecule stabilization of the GR 14-3-3 protein-protein interaction (PPI) |
| 11:50 | Daisy Paiva Because structure means function - Conformational changes in proteins measured with switchSENSE® |
| 12:10 | Charlotte Hodson Expanding Crystallographic methods for Fragment-based Drug Design |
| 12:30 | Keynote lecture: Jan Steyaert From Nanobodies to Megabodies for applications in cryo-EM |
| 13:10 | Lunch |
| 14:40 | Announcement of Posterprizes |
| END/FAREWELL Michael Sattler, Christian Ottmann | |
| 14:50 - 16:50 | Workshop BioSolveIT |